All Articles

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

Refinity's new license to turn plastic waste into jet fuel is more than a green initiative; it's a calculated move to rewire petrochemical supply chains.

Chinese innovator Kandi Technologies is aggressively expanding its off-road vehicle business, a strategic pivot that bets on deep localization over pure volume.

A renewed six-year contract for 300,000 state employees highlights Empower's market dominance and the critical role of supplemental retirement plans.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

Genius Group's massive share repurchase program aims to boost shareholder value, but a look at its financials reveals a high-stakes gamble. Is this a confident bet or a red flag?

A CAD$40M military contract validates NorthStar's space tech, bolsters Canada's sovereignty, and fuels its high-stakes journey to the public market.

GuideAI Health's new AI software, which scans for peripheral vascular disease, promises to slash diagnosis times and prevent amputations for millions.

Provincial ministers met to refocus their collective strategy, confronting the dual challenges of AI integration and unilateral federal policies on international students.

Wynn bets big on a multi-year deal with Netflix's Chef's Table. Is this the new gold standard for luxury hospitality or just an ultra-expensive menu?

A new product launch isn't just about a product. It's a strategic move to expose a 'quality crisis' and force transparency in the booming mushroom market.

Block Reign's CertiK audit for the Gnodi blockchain signals a new era of corporate-backed transparency in decentralized ecosystems, aiming for real-world utility.

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

With new CEO Eric Augustyn, an active investor from its own ranks, BiggerPockets plans a major platform overhaul to fortify its market dominance.

From my desk in The Engine Room, I analyze the blueprint behind Thirsty Buddha's bold leap from Canada into Costco UK and LA. This is more than a drink launch.

bioAffinity Technologies' new gene-silencing therapy kills common skin cancer cells in lab studies while leaving healthy cells untouched, hinting at a future without scars.

As work moves to the browser, so do the threats. Cybersecurity firm MirrorTab hires Colin Britton to scale its 'isolation' tech for a new reality.

AI is forcing a total rebuild of retail marketing. A new report finds leaders are hiring, but a huge skills gap could derail the entire transformation.

Masimo's FDA-cleared AI monitor for opioid risk does more than track vitals; it predicts danger, pushing healthcare from reactive alarms to proactive intervention.

How the 75-year-old denim icon is weaving its authentic heritage into the fabric of modern country music through a strategic, nationwide festival tour.